ERBB2 and breast carcinoma: These hybrid nanocarriers were subjected to evaluation of physicochemical properties, examination of cytotoxicity, investigation of cellular uptake mechanisms, and xenograft mice models in non-transformed BAEC and Her-2 breast cancer cell lines to verify their potential in breast cancer therapies.